This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05251/identifier/kegg-compound/
n12http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB05251/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05251/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05251/identifier/chemspider/

Statements

Subject Item
n2:DB05251
rdf:type
n3:Drug
n3:description
VRX496 is the first and only lentiviral vector therapy approved by the FDA for clinical trials, according to VIRxSYS. The backbone of VRX496 consists of a genetically engineered version of HIV in which all the infectious components are removed and replaced with the therapeutic payload—a long antisense sequence that targets the HIV envelope protein and cripples the virus.
n3:generalReferences
# Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B: Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther. 2004 Jun;9(6):902-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15194057 # MacGregor RR: Clinical protocol. A phase 1 open-label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum Gene Ther. 2001 Nov 1;12(16):2028-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11727736
n3:group
investigational
n3:indication
HIV infection
owl:sameAs
n12:DB05251
dcterms:title
VRX496
adms:identifier
n7:64143 n8:DB05251 n9:C07257 n10:57718
n3:mechanismOfAction
VRX496 is an autologous therapy that uses a patient’s own cells. Clinical sites collect white blood cells from individual patients by apheresis. VIRxSYS scientists purify the white blood cells to isolate CD4 T cells, which are transduced with VRX496. The genetically modified cells are expanded and reinfused into the patient. When HIV enters CD4 T cells to replicate, the antisense payload of VRX496 is transcribed, which binds the virus and destroys it. The goal is to repopulate a patient’s immune system with genetically engineered cells that promote immunity against HIV and prevent the progression to AIDS. Although not a cure, VRX496 could improve the quality of life for HIV patients by bringing viral loads down to low levels. This approach could slow or even reverse a patient’s progression to full-blown AIDS.
n3:IUPAC-Name
n4:271B3F06-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F0C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F0B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F08-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F09-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F0A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F04-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F02-363D-11E5-9242-09173F13E4C5 n4:271B3F05-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F03-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B3F12-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F13-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F0D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F0E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F10-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F0F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F11-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B3F18-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F1A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F1B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F17-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F16-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F19-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F07-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F14-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3F15-363D-11E5-9242-09173F13E4C5